Research Articles - Macular Degeneration
- The biopharmaceutical company Regeneron has received FDA approval for Eylea™, its treatment for wet age-related macular degeneration (AMD) that is as effective as currently prescribed wet AMD therapies such as Lucentis® but requires less-frequent ocular injections.
“Fewer injections with Eylea should translate to reduced risk of injection-related discomfort and complications for patients while not
- The National Eye Institute (NEI) reports that second-year results from its Comparison of AMD Treatments Trial (CATT) show that Lucentis and Avastin are similarly safe and effective in halting and reversing vision loss for people with wet age-related macular degeneration (AMD). The second-year CATT results, published on April 30, 2012, in the journal Ophthalmology, are consistent with
An innovative, targeted search technique known as whole-exome sequencing is dramatically reducing the time, effort and expense it takes to discover genetic defects that cause retinal disease. While the increasing raw power of genetic-screening technologies is continually accelerating the pace of gene discoveries, the whole-exome search strategy is a major leap forward.
A clinical trial for a human neural stem-cell therapy for people with dry age-related macular degeneration (AMD) has shown encouraging interim results. The rate of geographic atrophy — the loss of photoreceptors and supportive cells known as retinal pigment epithelium — was reduced by 70 percent in treated eyes versus
A new treatment for the wet form of age-related macular degeneration (AMD) has the potential to last up to three times longer than current treatments, according to the results of a pre-clinical study published, online, in the journal Biomaterials. Developed by researchers at Johns Hopkins Medical Center, the new drug and its delivery system were successfully tested in mice. While a
- Results from a clinical trial known as the Age-Related Eye Disease Study 2 (AREDS2), conducted by the National Eye Institute (NEI), have led researchers to recommend updating the formula for reducing risk of advanced age-related macular degeneration (AMD). The first AREDS called for using beta carotene, but now researchers believe that lutein and zeaxanthin appear to be more effective in reducing risk of the disease. In addition, beta carotene was linked to higher rates of lung cancer for current and former
Therapy that promotes independence and social activity may help prevent depression in people with low vision caused by age-related macular degeneration (AMD), which affects more than 10 million people in the United States. Known as behavior activation, the therapeutic approach reduced depression by nearly 50 percent in a clinical study of 188 people who averaged 84 years of age. Results from the research
Researchers from the University of California, Davis (UC Davis), have launched a Phase I clinical trial of CD34+ bone marrow stem cells (BMSC) for people with retinal conditions that cause vision loss from ischemia, or loss of blood flow, and cell degeneration. Led by Dr. Susanna Park, the investigative
The RIKEN Institute in Japan has started a clinical study for a wet age-related macular degeneration (AMD) treatment derived from induced pluripotent stem cells (iPSC) — mature cells that have been genetically reprogrammed to a stem cell-like state. The therapy involves replacement of a layer of cells known as